ArticleJournal of neurology2025
Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global trends and emerging hotspots in neuromyelitis optica spectrum disorder diagnostic research: A bibliometric analysis.Medicine · 2026Review
- Biomarkers for satralizumab treatment in neuromyelitis optica spectrum disorders: a prospective case series.BMC neurology · 2026Article
- Novel B-Cell targeting therapy with subcutaneous ofatumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSerum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) levels are potential biomarkers for disease activity and disability in Neuromyelitis Optica Spectrum Disorder (NMOSD), respectively; however, their clinical applications in NMOSD remain unclear. Therefore, this study aims to investigate the correlation between sGFAP and sNfL levels and the activity, severity of attacks, disability in patients with NMOSD.
methodsSGFAP and sNfL levels were measured in healthy controls (HCs) (n = 20) and patients with NMOSD (n = 86; 50 during attack and 50 in remission) using ultrasensitive single-molecule array assays. The relationships between the two biomarkers and different stages of NMOSD, the severe attacks, the Expanded Disability Status Scale (EDSS) scores, and the prognosis were analyzed.
resultsSNfL and sGFAP levels were significantly higher in patients with NMOSD than in HCs in the acute and remission phases (p < 0.05). The sGFAP level was higher in the acute phase than in the remission phase (P < 0.001). SNfL and sGFAP levels were higher in the severe myelitis attack group than in the severe optic neuritis attack group (p < 0.05). The EDSS ≥ 6 NMOSD group had significantly higher sNfL and sGFAP levels than the EDSS < 6 group (p < 0.05). SNfL and sGFAP levels in acute and remission stages increased with increasing EDSS scores (p < 0.05). SGFAP could discriminate patients with NMOSD with relapse from those under remission (p < 0.001).
conclusionsNfL and sGFAP may serve as biomarkers for NMOSD severity, activity, and motor disability.
Indexed as
Identifiers
40690027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.